At first, there was an incomprehensibly loud explosion. And out of that explosion, about 4.5 billion years afterward, emerged the world’s first rheumatologist. Only a few notable things have happened between these two events, but the most important dynamic has been the continuous expansion of our universe. If the speculations of many cosmologists are correct,…
Helping ACR/ARP members talk to lawmakers about rheumatology-related policy is a key part of the ACR’s advocacy efforts. A postcard-writing campaign to Congress highlights outreach efforts of a new member engagement working group.
Over our 25 years as rheumatologists, care has advanced greatly. We each completed our rheumatology training in the late 1990s when both infliximab and etanercept first arrived on the U.S. market, ushering in the era of biologics in rheumatology. Since this time, our greater understanding of the immunologic basis of many rheumatic diseases has translated…
Research & patients reap benefits when patients with rheumatic conditions get involved in patient-facing organizations & in clinical research planning.
As new chair of the Committee on Education, Marcy Bolster, MD, wants to foster opportunities for rheumatologists and other specialists to connect through education.
As of Jan. 1, rheumatology practices face significant changes in coding and reimbursement for telemedicine services, including new and deleted billing codes, updated Medicare policies and looming expiration of pandemic-related flexibilities.
By July 5, all providers who participate in federally funded healthcare programs, including Medicare and Medicaid, must provide language assistance programs for patients to meet requirements of Section 1557 of the Affordable Care Act.
The Voice of Rheumatology (VOR) Coalition convened last month at ACR Convergence 2024 in Washington, D.C., to discuss the pressing federal and state legislative priorities that will affect both the practice of rheumatology and patient care in the year ahead. The Coalition, composed of leading rheumatology professional societies and patient advocacy groups, gathered to examine…
A third extension of telemedicine flexibilities will continue to allow prescription of controlled substances via telemedicine without an in-person visit through the end of 2025.
Editor’s note: What research on psoriatic arthritis (PsA) presented at ACR Convergence 2024 has the greatest potential for a positive impact on clinical care, treatment options or serve as the basis for future research? That’s the question The Rheumatologist asked David S. Pisetsky, MD, PhD—our founding editor—to consider. Dr. Pisetsky, a professor of medicine and immunology…